The treatment of chronic myelogenous leukemia by interferon and cytosine-arabinoside: rational and design of the French trials. French CML Study Group
Guilhot, F.; Guerci, A.; Fiere, D.; Harousseau, J.L.; Maloisel, F.; Bouabdallah, R.; Guyotat, D.; Rochant, H.; Najman, A.; Nicolini, F.; Colombat, P.; Abgrall, J.F.; Ifrah, N.; Brière, J.; Bauters, F.; Navarro, M.; Morice, P.; Bordessoule, D.; Vilque, J.P.; Desablens, B.; Tertian, G.; Blanc, M.; Chastang, C.; Tanzer, J.
Bone Marrow Transplantation 17(Suppl 3): S29-S31
1996
ISSN/ISBN: 0268-3369 PMID: 8769697 Document Number: 462640
Document emailed within 1 workday
Related Documents
Guilhot, F. 1993: Interferon alfa and low-dose cytosine-arabinoside for the treatment of patients with chronic myelogenous leukemia in chronic phase. French CML Study Group Seminars in Hematology 30(3 Suppl 3: 24-25Takemoto, Y.; Sampi, K.; Kuraishi, Y.; Okabe, K.; Tamura, K.; Mizoguchi, H.; Saito, H.; Masaoka, T.; Ogawa, M. 1999: A prospective randomized trial of KRN8602 and cytosine arabinoside vs. daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukemia. the KRN8602 Leukemia Study Group International Journal of Hematology 70(1): 20-25
Ezaki, K. 2000: Interferon-alpha and cytosine arabinoside therapy in chronic myeloid leukemia Gan to Kagaku Ryoho. Cancer and ChemoTherapy 27(Suppl 2): 279-284
Gibelin, P.; Aumont, M.C.; Aupetit, J.F.; Bareiss, P.; Bouhour, J.B.; Desnos, M.; Dubourg, O.; Hagège, A.; Jondeau, G.; Komajda, M. 1999: Evaluation of a specific French scale of activity in chronic heart failure. A national multicenter study. Group for Cardiac Insufficiency and Cardiomyopathy of the French Society of Cardiology Archives des Maladies du Coeur et des Vaisseaux 92(9): 1175-1180
Ghaddar, H.M.; Plunkett, W.; Kantarjian, H.M.; Pierce, S.; Freireich, E.J.; Keating, M.J.; Estey, E.H. 1994: Long-term results following treatment of newly-diagnosed acute myelogenous leukemia with continuous-infusion high-dose cytosine arabinoside Leukemia 8(8): 1269-1274
Wysocki, M.; Nowaczyk-Michalak, A.; Pilecki, O.; Trybuś, L.; Balcar-Boroń, A. 1992: Jaundice following high--dose arabinoside cytosine in a child with acute myelogenous leukemia Acta Haematologica Polonica 23(3): 197-199
Vogler, W.R.; Velez-Garcia, E.; Omura, G.; Raney, M. 1989: A phase-three trial comparing daunorubicin or idarubicin combined with cytosine arabinoside in acute myelogenous leukemia Seminars in Oncology 16(1 Suppl 2: 21-24
Taguchi, H.; Kubonishi, I.; Takehara, N.; Uemura, Y.; Iwahara, Y.; Eguchi, T.; Miyagi, T.; Sugito, S.; Muneishi, H.; Tanaka, Y. 1992: Intensive induction chemotherapy of adult acute myelogenous leukemia by continuing daunorubicin, behenoyl-cytosine arabinoside, 6-mercaptopurine and prednisolone until marrow aplasia Gan to Kagaku Ryoho. Cancer and ChemoTherapy 19(9): 1309-1314
Nemet, D.; Labar, B.; Bogdanić, V.; Hauptman, E.; Jaksić, B.; Minigo, H.; Sertić, D.; Mrsić, M.; Pavletić, Z.; Kovacević, J. 1989: High dose cytosine arabinoside in the treatment of adult acute myelogenous leukaemia Bone Marrow Transplantation 4(Suppl 3): 42-44
1989: Factors related to outcome in intensive care: French multicenter study. The French Multicenter Group of ICU Research; The Inserm Unit 169 of Statistical and Epidemiological Studies Critical Care Medicine 17(4): 305-308
Hines, J.D.; Mazza, J.J.; Oken, M.M.; Bennett, J.M.; Adelstein, D.J.; Keller, A.; O'Connell, M.J. 1985: High-dose cytosine arabinoside and mAMSA induction and consolidation in patients with previously untreated de novo acute nonlymphocytic leukemia: Phase i Pilot Study for the Eastern Cooperative Oncology Group Seminars in Oncology 12(2 Suppl 3: 117-119
Guilhot, F. 1994: The role of interferon in the treatment of chronic myelogenous leukemia in chronic phase Nouvelle Revue Francaise d'Hematologie 36(Suppl 1): S39-S46
Lucotte, G.; Aouizérate, A.; Loreille, O.; Gérard, N.; Turpin, J.C. 1994: Trinucleotide repeat elongation in the huntingtin gene in Huntington's disease patients from 85 French families. The French HD Research Group Genetic Counseling 5(4): 321-328
Derulska, D.; Rokicka-Milewska, R. 1975: Cytosine arabinoside in the treatment of acute leukemia in children Pediatria Polska 50(6): 723-728
Tatsumi, N.; Masaoka, T.; Ueda, Y.; Senda, N. 1970: Treatment of leukemia with cytosine arabinoside--on the intensification of remission Gan no Rinsho. Japan Journal of Cancer Clinics 16(7): 706-712
Fenaux, P.; Chastang, C.; Degos, L. 1994: Treatment of newly diagnosed acute promyelocytic leukemia (APL) by a combination of all-trans retinoic acid (ATRA) and chemotherapy. French APL Group Leukemia 8(Suppl 2): S42-S47
Klener, P.; Háber, J. 1985: Treatment of refractory leukemia with high-dose cytosine arabinoside Neoplasma 32(1): 113-117
Pedersen, G.; Stentoft, J.; Pedersen, J.O.; Jensen, M.K. 1994: Treatment of acute myeloid leukemia in the elderly with low-dose cytosine arabinoside Ugeskrift for Laeger 156(43): 6380-6384
Cannistra, S.A.; Groshek, P.; Griffin, J.D. 1989: Granulocyte-macrophage colony-stimulating factor enhances the cytotoxic effects of cytosine arabinoside in acute myeloblastic leukemia and in the myeloid blast crisis phase of chronic myeloid leukemia Leukemia 3(5): 328-334
Negrier, S.; Douillard, J.-Y.; Gomez, F.éd.ér.; Lasset, C.; Chevreau, C.; Escudier, B. 2002: Interleukin-2 and interferon in metastatic kidney cancer. Experience of the French Immunotherapy Group Progres en Urologie: Journal de l'Association Francaise d'Urologie et de la Societe Francaise d'Urologie 12(2): 213-218